Adial Pharma Highlights U.S. Senate Backing For Expanded AUD Trial Endpoints, Reinforcing AD04 Development Strategy Focused On Craving Reduction

Author: Benzinga Newsdesk | August 20, 2025 08:41am

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today applauded recent U.S. Senate legislative support for expanding clinical trial endpoints beyond abstinence in substance use disorder treatments, including Alcohol Use Disorder (AUD). The U.S. Senate's move to encourage the FDA to develop new endpoints for AUD, such as reduced cravings, to enhance the regulatory pathway for new pharmaceutical candidates strongly reinforces Adial's clinical development strategy for AD04, its lead investigational drug, a serotonin-3 receptor antagonist, being developed for the treatment of AUD in individuals with heavy drinking and select genotypes.

Posted In: ADIL